CFTR modulators, especially triple therapy, significantly improve sinonasal inflammation and nasal polyp size in patients with cystic fibrosis.

Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder. Boehringer ...

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

In cystic fibrosis, ETI significantly reduced daily cough frequency and increased physical activity levels in patients aged 12 and older.

Pharmacology has a cation bias. For too long, research has focused heavily on sodium and potassium channels, often treating anion transport as a secondary ...

The firm made the announcements as part of its Q1 financial report, in which it posted $2.99 billion in revenue, up 8 percent ...

Topline data is on track for anticipated readout in the summer of 2026WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- ...